Company Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer’s disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.
The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson’s disease; and ACI-35.030, designs to stimulate a patient’s immune system to produce antibodies against pathological phosphorylated Tau.
In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease.
Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies.
Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3.
The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company.
AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
| Country | Switzerland |
| Founded | 2003 |
| IPO Date | Sep 23, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 161 |
| CEO | Andrea Pfeifer |
Contact Details
Address: Building B, EPFL Innovation Park Lausanne, 1015 Switzerland | |
| Phone | 41 21 345 91 21 |
| Website | acimmune.com |
Stock Details
| Ticker Symbol | ACIU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| CIK Code | 0001651625 |
| CUSIP Number | H00263105 |
| ISIN Number | CH0329023102 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrea Pfeifer Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Christopher Roberts | Chief Financial Officer and Vice President of Finance |
| Piergiorgio Donati | Chief Technical Operations Officer |
| Jean-Fabien Monin | Chief Administrative Officer |
| Howard Donovan | Chief Human Resources Officer |
| Madiha Derouazi | Chief Scientific Officer |
| Dr. Gary Anthony Waanders Ph.D. | Senior Vice President of Investor Relations and Corporate Communications |
| Alexandre Caratsch | General Counsel |
| Julian Snow | Vice President of U.S. Finance and Corporate Development |
| Dr. David T. Hickman | Head of AD - SME |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 6-K | Report of foreign issuer |
| Dec 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 10, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 6-K | Report of foreign issuer |
| Nov 5, 2024 | 6-K | Report of foreign issuer |
| Sep 27, 2024 | 144 | Filing |
| Sep 19, 2024 | 6-K | Report of foreign issuer |
| Sep 18, 2024 | 144 | Filing |
| Sep 17, 2024 | 6-K | Report of foreign issuer |